Literature DB >> 20445576

hOCT1 transcript levels and single nucleotide polymorphisms as predictive factors for response to imatinib in chronic myeloid leukemia.

A Bazeos, D Marin, A G Reid, G Gerrard, D Milojkovic, P C May, H de Lavallade, P Garland, K Rezvani, J F Apperley, J M Goldman, L Foroni, J S Khorashad.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2010        PMID： 20445576     DOI： 10.1038/leu.2010.86

Source DB:  PubMed          Journal:  Leukemia        ISSN： 0887-6924            Impact factor:   11.528


× No keyword cloud information.
  20 in total

1.  OCT-1 function varies with cell lineage but is not influenced by BCR-ABL.

Authors:  Jane R Engler; Andrew C W Zannettino; Charles G Bailey; John E J Rasko; Timothy P Hughes; Deborah L White
Journal:  Haematologica       Date:  2010-10-22       Impact factor: 9.941

2.  Poor adherence is the main reason for loss of CCyR and imatinib failure for chronic myeloid leukemia patients on long-term therapy.

Authors:  Amr R Ibrahim; Lina Eliasson; Jane F Apperley; Dragana Milojkovic; Marco Bua; Richard Szydlo; Francois-Xavier Mahon; Kasia Kozlowski; Christos Paliompeis; Letizia Foroni; Jamshid S Khorashad; Alex Bazeos; Mathieu Molimard; Alistair Reid; Katayoun Rezvani; Gareth Gerrard; John Goldman; David Marin
Journal:  Blood       Date:  2011-02-23       Impact factor: 22.113

3.  Genetic variations in influx transporter gene SLC22A1 are associated with clinical responses to imatinib mesylate among Malaysian chronic myeloid leukaemia patients.

Authors:  Siti Maziras Makhtar; Azlan Husin; Abdul Aziz Baba; Ravindran Ankathil
Journal:  J Genet       Date:  2018-09       Impact factor: 1.166

4.  Cellular uptake of imatinib into leukemic cells is independent of human organic cation transporter 1 (OCT1).

Authors:  Anne T Nies; Elke Schaeffeler; Heiko van der Kuip; Ingolf Cascorbi; Oliver Bruhn; Michael Kneba; Christiane Pott; Ute Hofmann; Christopher Volk; Shuiying Hu; Sharyn D Baker; Alex Sparreboom; Peter Ruth; Hermann Koepsell; Matthias Schwab
Journal:  Clin Cancer Res       Date:  2013-12-18       Impact factor: 12.531

Review 5.  Selection of therapy: rational decisions based on molecular events.

Authors:  Jamshid S Khorashad; Michael W N Deininger
Journal:  Hematol Oncol Clin North Am       Date:  2011-10       Impact factor: 3.722

6.  Whole-genome studies identify solute carrier transporters in cellular susceptibility to paclitaxel.

Authors:  Uchenna O Njiaju; Eric R Gamazon; Lidija K Gorsic; Shannon M Delaney; Heather E Wheeler; Hae Kyung Im; M Eileen Dolan
Journal:  Pharmacogenet Genomics       Date:  2012-07       Impact factor: 2.089

Review 7.  Pharmacogenetics and Pharmacogenomics of Targeted Therapeutics in Chronic Myeloid Leukemia.

Authors:  Aritro Nath; Jacqueline Wang; R Stephanie Huang
Journal:  Mol Diagn Ther       Date:  2017-12       Impact factor: 4.074

Review 8.  OCT1 and imatinib transport in CML: is it clinically relevant?

Authors:  D B Watkins; T P Hughes; D L White
Journal:  Leukemia       Date:  2015-07-09       Impact factor: 11.528

9.  The predictive value of human organic cation transporter 1 and ABCB1 expression levels in different cell populations of patients with de novo chronic myelogenous leukemia.

Authors:  Filip Razga; Zdenek Racil; Katerina Machova Polakova; Lucie Buresova; Hana Klamova; Daniela Zackova; Dana Dvorakova; Vaclava Polivkova; Petr Cetkovsky; Jiri Mayer
Journal:  Int J Hematol       Date:  2011-09-08       Impact factor: 2.490

10.  Hepatocyte nuclear factor 1 regulates the expression of the organic cation transporter 1 via binding to an evolutionary conserved region in intron 1 of the OCT1 gene.

Authors:  Valerie P O'Brien; Kristin Bokelmann; Jacqueline Ramírez; Karoline Jobst; Mark J Ratain; Jürgen Brockmöller; Mladen V Tzvetkov
Journal:  J Pharmacol Exp Ther       Date:  2013-08-06       Impact factor: 4.030
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.